Form 4: Lantern Pharma Director Acquires 53,844 Stock Options

Lantern Pharma Inc. Director D. Jeffrey Keyser acquired 53,844 stock options with an exercise price of $3.49, vesting over 12 and 24 months.

Summary

• D. Jeffrey Keyser, a Director of Lantern Pharma Inc. (LTRN), acquired 53,844 derivative securities in the form of stock options.
• The options were granted on January 9, 2026, under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan.
• The exercise price for all options is $3.49 per share.
• One grant of 25,000 options will vest in equal monthly increments over a 24-month period, commencing February 9, 2026.
• A second grant of 28,844 options will vest in equal monthly increments over a 12-month period, commencing February 9, 2026.
• All options have an expiration date of January 8, 2036.
• Following these transactions, D. Jeffrey Keyser directly beneficially owns 53,844 stock options.

Sentiment

Score: 7

Explanation: The acquisition of a significant number of stock options by a director is generally viewed positively as it aligns management's interests with shareholders and signals confidence in future performance, though it's not an outright purchase of shares.

Positives

• A director's acquisition of stock options indicates alignment of management incentives with shareholder interests and potential confidence in the company's future performance.
• The options were granted under an existing and approved stock incentive plan, demonstrating structured compensation practices.

Negatives

• The options are not immediately exercisable, as they are subject to vesting schedules of 12 and 24 months.
• The value of the options is dependent on the future stock price exceeding the exercise price of $3.49.

Risks

• The value of the stock options is subject to the volatility of Lantern Pharma Inc.'s common stock price.
• If the company's stock price does not rise above the exercise price of $3.49, the options may expire worthless.
• The options are subject to vesting conditions, meaning the director must remain with the company for the specified periods to fully realize the grants.

Future Outlook

The acquisition of these stock options by a director suggests a long-term commitment and an expectation of future growth and value creation for Lantern Pharma Inc., as the options' value is tied to the company's stock performance over the next decade.

Industry Context

Equity-based compensation, such as stock options, is a common practice in the biotechnology and pharmaceutical industries to attract, retain, and incentivize key personnel, aligning their interests with the long-term success of the company and its shareholders.

Comparison to Industry Standards

• The use of stock options with multi-year vesting schedules is a standard compensation practice for directors and executives in growth-oriented industries like biotechnology, similar to companies such as Moderna (MRNA) or BioNTech (BNTX) which frequently utilize equity incentives to align leadership with long-term R&D and commercialization goals.
• An exercise price set at the market price on the grant date is typical for incentive stock options, ensuring that the options only gain value if the company's stock price appreciates, a common structure seen across the S&P 500.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of stock options to a director can be seen as a positive signal, as it incentivizes the director to work towards increasing the company's stock price, benefiting all shareholders.
• Employees: The use of a stock incentive plan may signal a broader strategy of using equity compensation, potentially impacting employee morale and retention.

Next Steps

• The stock options will begin to vest in equal monthly increments starting February 9, 2026, over 12 and 24-month periods.
• The director will be able to exercise vested options to acquire common stock at the $3.49 exercise price until the expiration date of January 8, 2036.

Key Dates

Recommendation

The acquisition of stock options by a director suggests confidence in the company's future performance and aligns management incentives with shareholder interests. However, this Form 4 filing alone does not provide sufficient comprehensive financial or operational information for a strong buy or sell recommendation, warranting a 'hold' for further analysis of the company's fundamentals and market position.

Keywords

Lantern Pharma, LTRN, Stock Options, Form 4, Insider Transaction, Director Compensation, Equity Grant, D. Jeffrey Keyser, Biotechnology, Pharmaceutical